Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 13/20 | 1.00 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.84 |
| ▸ | POLB | P06746 | 1/20 | 0.79 |
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16512992 | 0.98 | TLR8 (1.00) | TLR8CXCR4POLBHTTCYP1A2 | |
| SCHEMBL2343059 | 0.95 | TLR8 (1.00) | TLR8CXCR4POLBHTTCYP1A2 | |
| SCHEMBL6196399 | 0.92 | CXCR4 (1.00) | TLR8CXCR4POLBHTTCYP1A2 | |
| SCHEMBL6197634 | 0.90 | CXCR4 (0.96) | TLR8CXCR4POLBHTTCYP1A2 | |
| SCHEMBL14447553 | 0.90 | CXCR4 (0.96) | TLR8CXCR4POLBHTTCYP1A2 | |
| SCHEMBL1520381 | 0.88 | POLB (1.00) | TLR8CXCR4POLBHTTCYP1A2 | |
| SCHEMBL7164854 | 0.88 | CXCR4 (0.93) | TLR8CXCR4POLBHTTCYP1A2 | |
| SCHEMBL6199065 | 0.84 | CXCR4 (0.85) | TLR8CXCR4POLBHTTCYP1A2 | |
| SCHEMBL22844184 | 0.84 | CXCR4 (0.84) | TLR8CXCR4POLBHTTCYP1A2 | |
| SCHEMBL16512990 | 0.83 | TLR8 (0.71) | TLR8CXCR4POLBHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180282734-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEAD AND NECK CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-04 | — | — | US | claimed |
| EP-3368034-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEAD AND NECK CANCER | Children's Hospital Medical Center (US) | 2018-09-05 | — | — | EP | claimed |
| US-9855273-B2 | Combination therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-01-02 | — | — | US | claimed |
| EP-2999470-B1 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2017-08-16 | — | — | EP | claimed |
| WO-2017075054-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEAD AND NECK CANCER | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2017-05-04 | — | — | WO | claimed |
| US-20170087162-A1 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2017-03-30 | — | — | US | claimed |
| US-9504706-B2 | Combination therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-11-29 | — | — | US | claimed |
| EP-2999470-A2 | COMBINATION THERAPY FOR MDS | Children's Hospital Medical Center (US) | 2016-03-30 | — | — | EP | claimed |
| US-20160038529-A1 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2016-02-11 | — | — | US | claimed |
| US-9168257-B2 | Combination therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2015-10-27 | — | — | US | claimed |
| US-20140350070-A1 | Combination Therapy for MDS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2014-11-27 | — | — | US | claimed |
| WO-2014190163-A2 | COMBINATION THERAPY FOR MDS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-11-27 | — | — | WO | claimed |
| US-20210292843-A1 | TREATMENT OF DISEASES ASSOCIATED WITH ACTIVATED IRAK | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-09-23 | — | — | US | disclosed |
| US-10640502-B2 | Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r) | NORTHWESTERN UNIVERSITY (US) | 2020-05-05 | — | — | US | disclosed |
| US-10471139-B2 | Toll-like receptor agonists | THE UNIVERSITY OF KANSAS (US) | 2019-11-12 | — | — | US | disclosed |
| EP-3532164-A1 | TREATMENT OF DISEASES ASSOCIATED WITH ACTIVATED IRAK | Children's Hospital Medical Center (US) | 2019-09-04 | — | — | EP | disclosed |
| WO-2006074991-A1 | NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | WO | disclosed |
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-10-20 | — | — | US | disclosed |
| EP-1487824-A1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003074515-A1 | DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234083-A1 | Diamino-pyrimidines and their use as angiogenesis inhibitors | TIE1, TEK, KDR | TLR8 2043/4885CXCR4 1139/4885POLB 420/4885 |
| US-20170087162-A1 | COMBINATION THERAPY FOR MDS | MCL1, IRAK4, IRAK3 | TLR8 640/4885CXCR4 797/4885POLB 3091/4885 |
| US-20180282734-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEAD AND NECK CANCER | IRAK1, IRAK4, IRAK2 | TLR8 216/4885CXCR4 2012/4885POLB 1191/4885 |
| US-20160038529-A1 | COMBINATION THERAPY FOR MDS | MCL1, IRAK4, IRAK3 | TLR8 640/4885CXCR4 797/4885POLB 3091/4885 |
| US-10471139-B2 | Toll-like receptor agonists | TLR1, TLR7, TLR8 | TLR8 3/4885CXCR4 300/4885POLB 1271/4885 |
| US-20140350070-A1 | Combination Therapy for MDS | MCL1, IRAK4, IRAK3 | TLR8 640/4885CXCR4 797/4885POLB 3091/4885 |
| US-10640502-B2 | Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r) | IRAK4, IRAK1, IRAK2 | TLR8 283/4885CXCR4 335/4885POLB 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.